Restoring Health & Mobility

Aziyo Biologics, Inc. was created by HighCape Partners with the mission of restoring health and mobility to the greatest number of patients possible. Our vision is to impact healthcare through the innovation of new solutions realizing the commercial potential of regenerative medicine. Aziyo is built on long-standing corporate partnerships and deep product development and biologics processing expertise.

AZO003-Interior-Large-Squares-2At Aziyo, we have witnessed first-hand that a transplanted ligament can enable mobility, a bone spinal implant can ease chronic pain, and a skin graft can bring much-needed relief to a burn victim.

These life-changing solutions fuel our utmost respect for the gift of donation and drive our dedication to scientific and operational excellence.

LEARN MORE ABOUT THE GIFT OF DONATION

Leadership

Leadership
Team

Ron Lloyd

Ron Lloyd
President and CEO
Read Bio

Michelle LeRoux Williams, Ph.D.

Michelle LeRoux Williams, Ph.D.
Chief Scientific Officer
Read Bio

Andrew M. Green

Andrew M. Green
EVP and GM, Cardiovascular Products
Read Bio

Darryl Roberts, Ph.D.

Darryl Roberts, Ph.D.
EVP and GM, Musculoskeletal Products
Read Bio

Jeff Hamet

Jeff Hamet
VP, Finance
Read Bio


Board of
Directors

Kevin Rakin
Executive Chairman
Read Bio

C. Randal Mills, Ph.D.
Board Member
Read Bio

Matt Zuga
Board Member
Read Bio

Steven Hochberg
Board Member
Read Bio

Ron Lloyd
Board Member
Read Bio

Newsroom

News

06.04.18 Ronald Lloyd Announced as New President and CEO of Aziyo Biologics

SILVER SPRING, MD. – June 4, 2018 – Aziyo Biologics, Inc., a fully integrated regenerative medicine company, announced today the appointment of Ronald (Ron) Lloyd as President and Chief Executive Officer of the company. Mr. Lloyd will be based in the Silver Spring, Maryland office with responsibility for all aspects of the rapidly growing Aziyo…

Read More
04.19.18 Aziyo Announces CanGaroo Strategic Co-Distribution Agreement with BIOTRONIK US

SILVER SPRING, MD. – Aziyo Biologics, Inc., a fully integrated regenerative medicine company, today announced that it has entered into a US co-distribution agreement for its CanGaroo® Bio Envelope with BIOTRONIK, Inc., a global leader in cardio- and endovascular medical technology. CanGaroo Bio Envelopes are a natural extracellular matrix (ECM) scaffold that securely hold cardiovascular…

Read More
03.22.18 Aziyo Biologics Expands Bone Repair Franchise with Launch of OsteGro

SILVER SPRING, Md., – March 22, 2018 – Aziyo Biologics, Inc., a fully integrated regenerative medicine company, announced today the launch of OsteGro, an allograft bone matrix that supports new bone growth in orthopedic surgical procedures. The launch of OsteGro further expands the company’s bone repair franchise. “We are excited to add OsteGro to our…

Read More
02.16.18 Aziyo and Cook Biotech Announce Further Expansion of the Bio Envelope Franchise into Additional Markets

SILVER SPRING, Md., and West Lafayette, Ind. – February 16, 2018 – Aziyo Biologics, Inc. and Cook Biotech Inc. today announced the expansion of the Aziyo Bio Envelope franchise by entering into additional exclusive global license agreements expanding the applications for the Bio Envelope product into the field of neuromodulation. The Bio Envelope is a…

Read More
02.01.18 University of Florida Health Physician is First to Implant Regenerative Bio Envelope for Defibrillator

SILVER SPRING, MD. – A University of Florida College of Medicine – Jacksonville physician has performed the world’s first implant of a regenerative bio envelope that protects a cardiac defibrillator implanted under the skin, a procedure that may offer better implant results and contribute toward better outcomes for patients. “This is truly a breakthrough because…

Read More
11.15.17 Aziyo Presents Positive Initial Data from Clinical Study of Biologic Extracellular Matrix Scaffold for Femoral Arterial Reconstruction

SILVER SPRING, MD. – Aziyo Biologics, Inc., a fully integrated regenerative medicine company, today announced positive results from PERFORM, a prospective, post-market study conducted in patients undergoing femoral arterial reconstruction using the company’s biologic extracellular matrix (ECM) scaffold.  There were no device-related adverse events or infections and primary patency was maintained in 97.6% of procedures. The…

Read More
11.03.17 Aziyo Launches CanGaroo Bio Envelope for Subcutaneous Implantable Cardioverter-Defibrillators

SILVER SPRING, MD. – Aziyo Biologics, Inc., a fully integrated regenerative medicine company, today announced the launch of a new CanGaroo Bio Envelope specifically for use with subcutaneous implantable cardioverter-defibrillators (S-ICDs). This is the only cardiac implantable electronic device (CIED) envelope available for use with S-ICDs. CanGaroo is a natural extracellular matrix (ECM) scaffold that is…

Read More
08.29.17 Aziyo Completes Enrollment in Prospective Post Market Study of CanGaroo ECM Envelope

SILVER SPRING, MD. – Aziyo Biologics, Inc. a fully integrated regenerative medicine company, today announced completion of patient enrollment in SECURE, a prospective post market study of 1,000 patients treated with CanGaroo® ECM® Envelope in conjunction with cardiac implantable electronic device (CIED) placement. The CanGaroo ECM Envelope is intended to securely hold a CIED to…

Read More
05.31.17 Aziyo Continues Building New Breed of Regenerative Medicine Company

Commercial portfolio expanded with acquisition of CorMatrix® products

Read More
11.05.15 HighCape Partners and Tissue Banks International Partner to Create Cutting Edge Regenerative Medicine Company Aziyo Biologics

HighCape Partners and Tissue Banks International Partner to Create Cutting Edge Regenerative Medicine Company Aziyo Biologics

Read More

Investors

Aziyo Biologics is supported by HighCape Partners, a growth equity fund focused on investing in commercial-stage life sciences companies, Deerfield Management, an investment management firm, Midcap Financial, a specialty finance firm, and Keralink, a leading network of ocular centers.